CITIC Group Buys Stake In China Central Pharmaceuticals
This article was originally published in PharmAsia News
CITIC Asset Management, a subsidiary of CITIC Group, has injected RMB 100 million into China Central Pharmaceuticals' subsidiary Wuhan Pharmaceutical Group. China Central plans to go public the second half of 2009 on Hong Kong's main board but it does not discount listing on other stock markets. Upon China Central's listing as a full entity, CITIC Asset Management will become one of its shareholders by share swap. The investor expresses confidence in China Central's business model; the latter is forming an alliance of pharmaceutical distributors to strengthen their bargaining power in the industry. So far, 53 distribution companies covering major cities and regions across China have participated in the scheme. (Click here for more - Chinese Language)
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.